Edison Investment Research - Okoworld AG (VVV3) Oekoworld - Continued growth in AUM

Report

Edison Investment Research

Milosz Papst

Oekoworld - Continued growth in AUM

Ã–KOWORLD (Ã–WAG) has demonstrated over the past months that despite volatile market conditions, it can leverage the positive sentiment towards sustainable investment to drive growth in assets under management (AUM) beyond â‚¬1.3bn. The healthy ytd performance allowed most of the funds managed by its subsidiary, Ã–koworld LUX, to rebound to the record high levels set in Q318. However, we note that H119 results were largely assisted by a dividend payment from an Ã–WAG-related company. To generate significant performance fees in FY19, which are one of Ã–WAGâ€™s key earnings drivers, the funds need to post strong positive returns in H219 as well.

14/08/2019 5 EN

Underlying

Okoworld AG

OEKOWORLD AG, formerly Versiko AG, is a Germany-based investment consulting company and funds operator that focuses on ecological investments. The Company serves both private customers and institutional investors, banks and other financial services provider. It offers the pension insurances Oekoviola, Versirente and Veresikid, as well as the investment funds Oekoworld Oekovision Classic, Oekoworld Growing Markets 2.0, Oekoworld Oekotrust, Oekoworld Klima, Oekolworld Water For Life, Oekovision Garant 20 and New Energy Fund. The Company conducts sustainability research in order to identify potential investment possibilities and asset and fund management through OEKOWORLD LUX SA, a Luxembourg-based subsidiary.

See profile

DE0005408686 Germany

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Milosz Papst

Other Reports on these Companies

BankM AG

Kapitalmarktumfeld belastet, Konzernhalbjahresüberschuss leicht unter Vorjahr

MiFID II – Hinweis: Diese Studie wurde auf Grundlage einer vertraglichen Vereinbarung im Auftrag des Emittenten erstellt und von diesem vergütet. Die Studie wurde gleichzeitig allen Interessenten öffentlich zugänglich gemacht. Der Erhalt dieser Studie gilt somit als zulässiger geringfügiger nichtmonetärer Vorteil im Sinne des § 64 Abs. 7 Satz 2 Nr. 1 und 2 des WpHG. Wie vorab gemeldet lag der Halbjahresüberschuss 2023 der Ökoworld AG (ISIN DE0005408686, Open Market, VVV3 GY) bei € 12,53 Mio. (H1 2022: 13,67 Mio.). Der Umsatz zeigte einen Rückgang auf € 33,2 Mio. (H1 22: € 37 Mio.). Die Entwic...

November 14, 2023 November 14, 2023 8 DE

BankM AG

H1 schwächer als im Vorjahr, Bewertung bleibt attraktiv

MiFID II – Hinweis: Diese Studie wurde auf Grundlage einer vertraglichen Vereinbarung im Auftrag des Emittenten erstellt und von diesem vergütet. Die Studie wurde gleichzeitig allen Interessenten öffentlich zugänglich gemacht. Der Erhalt dieser Studie gilt somit als zulässiger geringfügiger nichtmonetärer Vorteil im Sinne des § 64 Abs. 7 Satz 2 Nr. 1 und 2 des WpHG. Die vorab gemeldeten Konzernhalbjahreszahlen der ÖKOWORLD AG (ISIN DE0005408686, Open Market, VVV3 GY) mit einem Halbjahresüberschuss 2023 von € 12,5 Mio. (H1 2022: 13,7 Mio.) lagen leicht unter unseren Erwartungen – wir passen un...

August 21, 2023 August 21, 2023 9 DE

BankM AG

Marktumfeld sorgt für schwaches Kapitalanlagegeschäft, Dividende bleibt stabil

MiFID II – Hinweis: Diese Studie wurde auf Grundlage einer vertraglichen Vereinbarung im Auftrag des Emittenten erstellt und von diesem vergütet. Die Studie wurde gleichzeitig allen Interessenten öffentlich zugänglich gemacht. Der Erhalt dieser Studie gilt somit als zulässiger geringfügiger nichtmonetärer Vorteil im Sinne des § 64 Abs. 7 Satz 2 Nr. 1 und 2 des WpHG. Die 2022er Zahlen der ÖKOWORLD AG (ISIN DE0005408686, Open Market, VVV3 GY) lagen unter unseren Erwartungen, da sich die schwache Kapitalmarktstimmung auch im zweiten Halbjahr 2022 (insbesondere Q3) fortsetzte. Mit einem Umsatz vo...

May 23, 2023 May 23, 2023 9 DE

discoverIE Group - FY24 EPS in line; good margin progress

discoverIE anticipates reporting FY24 underlying EPS in line with board expectations. After a period in mid-FY24 of working down inventory, customers appear to be reverting to normal ordering patterns, with Q424 organic revenue growth of 2% y-o-y and 11% q-o-q and a strong pipeline of design wins at year-end. We have revised our forecasts to reflect lower revenue, partly due to a disposal, but maintain our profit forecasts, which results in operating margin expansion in FY24 and FY25.

4h / 29m 4h / 29m 1 EN

Sean Conroy

Sean Conroy

Ultimovacs - Steadfast commitment to UV1 progression

Despite the recent setback with the INITIUM trial (first-line treatment of patients with unresectable or metastatic malignant melanoma), Ultimovacs has reinstated its commitment to press on with its clinical development of its cancer vaccine, UV1, across other target indications. The principal near-term focus will be on the anticipated results of Phase II FOCUS (head and neck cancer) and DOVACC (ovarian cancer) trials in Q324 and H125, respectively, and will inform its subsequent strategic direction. To remain funded to these milestones, the company has enforced stringent cost control measures...

April 18, 2024 April 18, 2024 1 EN

Sean Conroy

Sean Conroy

OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle

OSE has announced that its licence agreement with AbbVie has cleared antitrust review and has become effective. As previously noted, this is expected to support OSE’s runway extension into 2026, past key milestones and readouts for in-house assets Tedopi (non-small cell lung cancer, US Phase III trials expected to commence in Q224) and Lusvertikimab (ulcerative colitis, Phase II readouts expected in mid-2024). Following the Federal Communications Commission (FCC) mandatory waiting period, OSE is expected to receive the negotiated US$48m upfront payment from AbbVie imminently, as part of its gl...

April 18, 2024 April 18, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Oekoworld - Continued growth in AUM

Kapitalmarktumfeld belastet, Konzernhalbjahresüberschuss leicht unter Vorjahr

H1 schwächer als im Vorjahr, Bewertung bleibt attraktiv

Marktumfeld sorgt für schwaches Kapitalanlagegeschäft, Dividende bleibt stabil

discoverIE Group - FY24 EPS in line; good margin progress

Ultimovacs - Steadfast commitment to UV1 progression

OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe